Mar 21, 2023 / 05:30PM GMT
Paul Richard Knight - KeyBanc Capital Markets Inc., Research Division - MD & Senior Analyst
This is Paul Knight, the analyst at a KeyBanc on the life science industry covering Repligen. It's great to have with us today Jon Snodgres, the CFO; and Tony Hunt, CEO of Repligen. And I think that's it from Repligen, right, Tony?
Anthony J. Hunt - Repligen Corporation - President, CEO & Director
Yes. Yes. We've got Sondra and Steven here as well, but Jon, myself will probably be doing most of talking.
Paul Richard Knight - KeyBanc Capital Markets Inc., Research Division - MD & Senior Analyst
Okay. I know you may have been on the investor (inaudible) a little while already this year, but if you want to make a few opening comments about the market, please do. And then we'll have some questions develop.
Anthony J. Hunt - Repligen Corporation - President, CEO & Director
Yes. Maybe start, Paul, with where Repligen is coming out of 2022 and what we think are maybe things
Repligen Corp at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum (Virtual) Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers